Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TTK | P33981 | 1/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
| ▸ | ITK | Q08881 | 7/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.46 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672674 | 0.80 | IDO1 (0.78) | IDO1KDM4EGAAALDH1A1ALPL | |
| SCHEMBL5516155 | 0.78 | MAPKAPK2 (0.57) | ITKAURKAMAPKAPK2MAP2K4HTR2A | |
| SCHEMBL758466 | 0.78 | FLT3 (0.62) | IDO1ITKFGFR1MAPKAPK2PDPK1 | |
| SCHEMBL29053552 | 0.77 | KDM4E (0.53) | IDO1KDM4EGAAALDH1A1ALPL | |
| Hydrochloric Acid SCHEMBL6370902 | 0.77 | AXL (0.54) | MAPK10ITKFGFR1AURKAMAPKAPK2 | |
| SCHEMBL10214011 | 0.76 | LRRK2 (0.52) | LRRK2MAPKAPK2 | |
| Hydrochloric Acid SCHEMBL6370465 | 0.75 | MAPK10 (0.68) | MAPK10LRRK2AURKAMAPKAPK2PDPK1 | |
| SCHEMBL12124010 | 0.75 | FGFR2 (0.48) | GAAITKFGFR1MAPKAPK2PDPK1 | |
| SCHEMBL3709693 | 0.75 | TTK (0.58) | TTKMAPK10ITKFGFR1MAPKAPK2 | |
| SCHEMBL5510153 | 0.75 | MKNK1 (0.67) | TTKLRRK2MAPKAPK2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101440092-B | 2-indazole-4-aza indole-5-amino derivatives, and preparation and use thereof | UNIV ZHEJIANG | 2010-11-17 | — | — | CN | claimed |
| CN-101440092-A | 2-indazole-4-aza indole-5-amino derivatives, and preparation and use thereof | UNIV ZHEJIANG (CN) | 2009-05-27 | — | — | CN | claimed |
| EP-3118189-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | Phenex Pharmaceuticals AG (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-9458104-B2 | Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγ | PHENEX PHARMACEUTICALS AG (DE) | 2016-10-04 | — | — | US | disclosed |
| EP-2882710-B1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | PHENEX PHARMACEUTICALS AG (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-20150344423-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | PHENEX PHARMACEUTICALS AG (DE) | 2015-12-03 | — | — | US | disclosed |
| EP-2882710-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | Phenex Pharmaceuticals AG (DE) | 2015-06-17 | — | — | EP | disclosed |
| CN-104603105-A | Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ROR Gamma | PHENEX PHARMACEUTICALS AG | 2015-05-06 | — | — | CN | disclosed |
| WO-2014023367-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | PHENEX PHARMACEUTICALS AG (DE) | 2014-02-13 | — | — | WO | disclosed |
| US-8609686-B2 | Substituted azabicyclic compounds and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| EP-1962830-B1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| WO-2007076348-A2 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. | 2004-05-13 | — | — | US | disclosed |
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | IDO1 636/4885KDM4E 317/4885GAA 2278/4885 |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | IDO1 636/4885KDM4E 317/4885GAA 2278/4885 |
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | MAP3K19, MAP3K1, MAP3K7 | IDO1 1267/4885KDM4E 1574/4885GAA 3935/4885 |
| US-20150344423-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | RORA, RORB, RORC | IDO1 1603/4885KDM4E 1805/4885GAA 3469/4885 |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | IDO1 636/4885KDM4E 317/4885GAA 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.